Losing body weight sounds straightforwardly good, but where that weight comes from matters enormously. When older adults lose weight quickly, a meaningful portion can come from muscle tissue rather than fat. Losing muscle, a condition researchers call sarcopenia, is linked to falls, reduced mobility, and a lower quality of life. This concern has become more pressing as GLP-1 receptor agonist peptides have moved to the center of obesity and diabetes research, because the substantial weight loss they produce may carry a hidden cost for muscle.
A clinical trial now recruiting at two Israeli medical centers is designed to test one practical answer to that problem: pair a GLP-1 receptor agonist with structured exercise and personalized nutrition, and see whether the combination preserves muscle and physical function better than the drug alone. The trial record, registered as NCT06497595, focuses on adults aged 65 and older who have both type 2 diabetes and overweight or obesity, a population where sarcopenia risk is already elevated.
The study is not asking whether the peptide works for weight loss or blood sugar control. That ground has been covered elsewhere. Instead it is asking a narrower and arguably more urgent question: when older people use this class of therapy, does a formal lifestyle program meaningfully protect their muscle and functional ability over the course of roughly six months?
The core research question
Semaglutide belongs to a class of molecules called glucagon-like peptide-1 receptor agonists, or GLP-1 RAs. They work by mimicking a gut hormone that regulates appetite and blood sugar. The trial uses a subcutaneous, once-weekly formulation, starting participants at a low dose and escalating every four weeks until a maintenance level is reached by week 16. Treatment continues through week 26.
Every participant in the trial receives the peptide. What differs between the two groups is what comes alongside it. One group, called the multidisciplinary intervention group, receives weekly online group exercise sessions plus two additional home-based sessions per week, as well as personalized nutrition counseling with a registered dietitian every two to four weeks. The other group, the control, receives general health recommendations and continues its usual routine. Researchers will then compare outcomes across a detailed battery of measurements collected at four points during the trial.
Why older adults with diabetes are the focus
Adults 65 and older already face age-related muscle loss as a background condition. Adding type 2 diabetes raises the risk further, because the metabolic disruption of the disease can impair the signals that build and maintain muscle. Obesity complicates things again, since excess fat can mask muscle loss on a standard scale, meaning someone can be losing muscle while their overall weight barely changes.
GLP-1 receptor agonists are increasingly used in this population, so understanding their effect on muscle composition in older adults is a practical and timely question. The trial record notes that the research team includes specialists in endocrinology, nutritional science, physical therapy, fitness training, medical imaging, and biostatistics, reflecting the multidisciplinary nature of the problem.
How researchers will measure muscle and function
The trial uses an unusually broad measurement toolkit. Body composition is assessed with three complementary methods: whole-body MRI, dual-energy X-ray absorptiometry (DXA), and bioelectrical impedance analysis (BIA). Using all three together gives researchers a more complete picture of how fat mass and lean mass shift over time.
Functional ability is evaluated with several validated physical tests. The Timed Up and Go test measures how quickly a participant can rise from a chair, walk three meters, turn, and return. The Short Physical Performance Battery assesses balance, repeated chair stands, and walking speed as a combined score. A six-minute walk test captures aerobic capacity by recording how far participants can walk in that period. The 10-meter walk test records gait speed over a measured distance.
Strength is assessed separately, with a 30-second chair stand test counting how many times someone can rise from sitting without using their arms, and a hand-grip strength test using a calibrated dynamometer. Both measures appear in sarcopenia screening guidelines because they predict real-world outcomes like falls and hospitalization.
Frailty is also formally screened using the Fried scale, which flags unintentional weight loss, self-reported exhaustion, low physical activity, slow gait speed, and low grip strength. Blood markers including HbA1c are collected at three visits to track diabetes control across the trial period. A subset of consenting participants will also undergo optional muscle biopsies at the start and end of the study, offering a tissue-level view of what is happening inside the muscle itself.
What the lifestyle intervention actually involves
The exercise component of the multidisciplinary intervention is designed to be accessible. Sessions are delivered online via video platform, which reduces the barrier of travel for older participants. One supervised group session per week is supplemented by two unsupervised home sessions. Researchers monitor adherence through weekly phone calls, and completing at least two of the three weekly sessions is defined as good compliance.
The nutrition component is individualized rather than one-size-fits-all. A certified dietitian meets virtually with each participant every two weeks for the first month, then every four weeks for the remainder of the study. Participants fill out three-day food diaries before each clinic visit, giving researchers a detailed picture of actual dietary patterns rather than self-reported estimates. The trial record specifically mentions protein consumption as a tracked variable, reflecting the known role of adequate dietary protein in maintaining muscle mass.
Sarcopenia screening within the trial
The trial uses the SARC-F questionnaire as a screening tool for sarcopenia risk. SARC-F asks about self-reported difficulty with strength, walking, rising from a chair, climbing stairs, and history of falls. Each domain is scored zero to two, for a maximum of ten. A score of four or above indicates the need for further evaluation. This tool is used at the population level to identify who is at risk, and the trial incorporates it alongside the objective functional and imaging measures to give a fuller clinical picture.
The Fried frailty scale adds another layer. Participants are categorized as robust, pre-frail (two criteria met), or frail (three or more criteria met). Tracking these categories across the trial period allows researchers to see whether the lifestyle intervention shifts people along the frailty spectrum, not just improves individual measurements.
What this trial does not tell us yet
The trial is still recruiting as of the date this article was prepared. No outcome data are available. The trial record describes the design and measurement plan, not results. Readers curious about the findings will need to wait for the investigators to publish.
The study is also designed for a specific population: adults 65 and older, with both type 2 diabetes and overweight or obesity, at two centers in Israel. Whether findings would generalize to younger adults, those without diabetes, or populations in other healthcare settings is a separate question that this trial cannot answer.
The broader research question it is exploring, whether structured lifestyle support can reduce muscle loss associated with GLP-1 receptor agonist use in older adults, is an active and important area of investigation. Early data from smaller studies and mechanistic research suggest that resistance exercise and adequate protein intake can help preserve lean mass during caloric restriction, but a rigorous randomized trial in this specific population and treatment context is what this study aims to provide.
